Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Financing Activities (2016 - 2025)

Ptc Therapeutics has reported Cash from Financing Activities over the past 14 years, most recently at $302.5 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $302.5 million for Q4 2025, up 1042.78% from a year ago — trailing twelve months through Dec 2025 was $331.1 million (up 29.4% YoY), and the annual figure for FY2025 was $331.1 million, up 29.4%.
  • Cash from Financing Activities for Q4 2025 was $302.5 million at Ptc Therapeutics, up from $15.2 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for PTCT hit a ceiling of $620.5 million in Q4 2023 and a floor of -$140.0 million in Q3 2022.
  • Median Cash from Financing Activities over the past 5 years was $4.2 million (2021), compared with a mean of $71.1 million.
  • Peak annual rise in Cash from Financing Activities hit 6857.23% in 2022, while the deepest fall reached 4804.13% in 2022.
  • Ptc Therapeutics' Cash from Financing Activities stood at $4.4 million in 2021, then skyrocketed by 6857.23% to $302.9 million in 2022, then skyrocketed by 104.84% to $620.5 million in 2023, then crashed by 95.73% to $26.5 million in 2024, then surged by 1042.78% to $302.5 million in 2025.
  • The last three reported values for Cash from Financing Activities were $302.5 million (Q4 2025), $15.2 million (Q3 2025), and $4.0 million (Q2 2025) per Business Quant data.